Refine by
Patient Survival Articles & Analysis
34 news found
The primary focus of the TIGeR-PaC study is to administer targeted therapy to pancreatic cancer patients safely and without transmission to non-targeted areas. The end goals are to determine whether this targeted method of delivering chemotherapy can extend survival while also improving quality of life. ...
ByxCures
Non-responders had lower DS and survival than patients with high DS. Conclusions from the study suggest that DS-low MDS patients should be considered for novel combination therapy at the time of diagnosis. ...
ITM is developing ITM-11 to provide patients with a new, targeted treatment approach to these difficult-to-treat tumors with the goal to improve clinical outcome and quality of life. ...
There remains an unmet need to extend survival for patients with these life-threatening diseases and XPOVIO® presents Taiwan physicians and patients with a new novel addition to existing therapies. ...
“There’s a clear unmet need for earlier and more accurate cancer diagnostics and INOVIQ is developing a multi-product diagnostics pipeline for different cancers and test purposes to improve patient outcomes and survival,” she said. “Our diagnostics pipeline currently includes SubB2M-based tests in development for monitoring breast and ...
Proprietary microRNA signature (miRisk) may support immunotherapy treatment decisions as a blood-based complementary diagnostic Results published in Journal of Thoracic Oncology Clinical and Research Reports Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today announced a publication in the Journal of Thoracic ...
RP-L201 well-tolerated with durable CD18 expression for all patients in Phase 2 pivotal trial 100% overall survival in patients at one year after RP-L201 infusion based on Kaplan-Meier estimate All patients showed clinical reversal of disease course, including statistically significant reduction in all-cause hospitalizations ...
Initiated posoleucel registrational study to prevent six devastating viral infections and now enrolling high-risk allo-HCT patients in the U.S., Western Europe and Asia FDA granted RMAT designation to posoleucel for Phase 3 multi-virus prevention indication with an estimated annual addressable patient population of 40,000 allo-HCT patients ...
ByKalaris
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces new data validating the benefits of the Company’s BVA-100 blood test (BVA) in improving survival for advanced heart failure patients with left ventricular assist device (LVAD). ...
Importantly, a preliminary interim analysis[1] of patient survival following alfapump implantation in the Roll-In Cohort indicated a mean survival probability of 70% at 12 months. ...
The Phase 2 study is designed to assess whether the addition of SCIB1 to pembrolizumab (Keytruda®) will result in an improvement in the tumour response rate, progression-free survival and overall survival in patients with advanced melanoma, who are also eligible for treatment with pembrolizumab. ...
ByScancell
As 90% of allo-HCT patients reactivate at least one of these viruses, there is a large global market opportunity for the prevention of devastating viral diseases, with an estimated addressable patient population of 40,000 allo-HCT patients annually. ...
ByKalaris
Amir Jazaeri, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, and reported at the annual meeting of Society of Gynecologic Oncology (SGO) in Phoenix, AZ, that a subset of patients with ovarian clear cell carcinoma (OCCC) treated with immune checkpoint inhibitors lived significantly longer (had increased overall ...
City of Hope, one of the largest cancer research and treatment organizations in the United States, and Osel Inc., a company developing live biotherapeutic products for modulation of the human microbiome, today announced Phase 1 trial data showing that use of the live biotherapeutic CBM588 (Clostridium butyricum MIYAIRI 588® strain) plus immunotherapy medicine nivolumab/ipilimumab ...
Results from the Phase III ARASENS trial evaluating darolutamide plus androgen deprivation therapy (ADT) and docetaxel showed a statistically significant increase in overall survival with a reduction in the risk of death by 32.5% compared to ADT plus docetaxel (HR=0.68, 95% CI 0.57-0.80; P Consistent benefits were also seen across secondary endpoints, which are of key ...
ByBayer AG
Ascensia plans to make the E3 sensor, which can be used for up to six months, available to patients in the U.S. during the second quarter of 2022. Robert Schumm, President at Ascensia Diabetes Care, said, “As the world’s first and only long-term CGM system, Eversense is truly innovative and the prospect of using a single sensor for up to six months is huge step ...
Lymphatic Research and Biology Publishes Data on PREVENT, the Largest Randomized Trial to Assess Lymphedema Prevention L-Dex Technology Provides a New Standard Approach for Prevention of Cancer-Related Lymphedema ImpediMed Limited (ASX: IPD), a global medical technology company using bioimpedance spectroscopy (BIS) to generate powerful data to maximize patient ...
The LightDeck® Analyzer’s inflammation panel is expected to help healthcare providers determine the status of a patient’s health and the severity of their condition. The results could inform triage and treatment decisions on-site and in real-time, potentially making a significant difference in patient outcomes. ...
About the Carillon Mitral Contour System Cardiac Dimensions is reimagining the solutions available to patients suffering from heart failure by providing a therapy that allows patients to live longer, higher quality lives. ...
Liver transplant is generally a safe process with very good survival rates. However, there are certain factors that may influence the success rate, and it varies from person to person. The factors also tend to determine how long a patient will survive after a successful surgery. Well, these factors include age, lifestyle habits, overall health, ...